House Oversight — Estate records
- Pages
- 2
- Text
- Searchable
Text as released
Machine-read from the scan. Names, dates and numbers can be misread — check anything you rely on against the original page.
From: Sent: To: Subject: Attachments: Importance: Richard Kahn 12/15/2016 5:46:20 PM jeffrey E. [jeeyacation@gmail.com] Fwd: US Healthcare Year Ahead...Buy ACAD, AGN, ANTM, CELG, CVS, DHR, EW, EVHC, RARE, REGN, WBA image001jpg01D256A2F263C080.jpg; image001gif01D256C23AC52B10.gif High attached are equity healthcare ideas Richard Kahn HBRK Associates Inc. 575 Lexington Avenue 4th Floor New York, NY 10022 tel fa cell________________________ Begin forwarded message: From: "Ens, Amanda" Subject: US Healthcare Year Ahead...Buy ACAD, AGN, ANTM, CELG, CVS, DHR, EW, EVHC, RARE, REGN, WBA Date: December 15, 2016 at 10:59:39 AM EST To: "Rich Kahn" __________ Reply-To: "Ens, Amanda" The US team is out with their 2017 Year Ahead this morning (link) running through ALL sub-sectors with each analysts top pick into the new year. op Picks — ACAD, AGN, ANTM, CELG, CVS, DHR, EW, EVHC, RARE, REGN, WBA Washington DC Backdrop Given the clean sweep by the GOP & uncertainty around the ACA, key attention is paid by Andy Bressler to a review of the various scenarios that could play out early next year. With a repeal likely to happen well before a replace (essentially via the Budget Reconciliation process in Jan/Feb), Andy notes this is likely to include a repeal of both health insurance exchange subsidies & a phase-down of Medicaid expansion funding (albeit with a two or three year transition period). He also expects a repeal of many of the larger HC related taxes in the ACA, including the HIX ($14.3bn in 2018), Medtech Tax (2.3%), pharma industry tax ($4.1bn in 2018) & Cadillac tax (effective 2020). As for the views by analysts... Biotech (+) — believe sector will outperform largely as pricing risk has diminished (although will remain in pockets) but pipelines/growth remains. Ying's top picks are CELG & REGN; Tazeen's top picks are kCAD & RARE. Spec Pharma (-) — headwinds remain w/ Sumant's top pick AGN given lower risk to reimbursement pressures & […]